About this trial
Environmental pollution from plastics has become a significant global issue, with microplastics-tiny particles resulting from plastic degradation-being increasingly detected in various environments, including aquatic ecosystems, soil, and air. These particles can enter the human body through ingestion or inhalation. Despite growing concerns, little is known about the prevalence and types of microplastics in human lungs. Some studies suggest that microplastics may negatively impact respiratory function and lead to lung diseases. Hypothetically, they could cause inflammation, metabolic disorders, and contribute to lung cancer development. However, research is still in its early stages, and conclusive evidence about the mechanisms linking microplastics to negative health effects is lacking. This study aims to quantify and characterize microplastics in the lung parenchyma and lymph nodes of patients with lung cancer and other respiratory diseases. Tissue samples will be collected during surgeries, and microplastic particles will be detected using FTIR microspectroscopy. The research may contribute to a better understanding of the role of microplastics in the development of respiratory diseases.
Eligibility criteria
Qualifiers
patients undergoing surgery for lung cancer, emphysema, interstitial lung diseases, or other respiratory conditions,
patients undergoing lung transplantation (lungs removed from transplant recipients),
age 18 years or older,
ability to provide informed consent.
Disqualifiers
patients with a history of recent or ongoing chemotherapy, immunotherapy, or radiation therapy,
inability or unwillingness to provide informed consent,
previous lung surgeries,
insufficient tissue or blood samples available for analysis due to technical or procedural reasons.
Trial design
Treatments tested in this trial
- Not listed